Study Summary
This trial is testing the combination of venetoclax, lenalidomide, and rituximab hyaluronidase to treat patients with relapsed or refractory low-grade lymphoma. The goal is to find the maximum tolerated dose of venetoclax and to learn about the side effects of this combination.
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia (CLL)
- Refractory Marginal Zone Lymphoma
- Refractory Follicular Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Indolent Adult Non-Hodgkin Lymphoma
- Recurrent Marginal Zone Lymphoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Time from study registration to death from any cause, assessed at 2 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Venetoclax · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is this experiment actively inviting participation from volunteers?
"Indeed, the trial is currently admitting participants. According to clinicaltrials.gov, it was first posted on October 16th 2020 and edited most recently on April 7th 2022; 30 individuals are needed at a single site for participation." - Anonymous Online Contributor
What indications is Venetoclax commonly proscribed for?
"Venetoclax is a popular medication for treating diffuse large b-cell lymphoma (dlbcl). Additionally, it can be used to address inflammatory breast cancer (ibc) and other B-Cell Lymphomas that have not responded to prior systemic chemotherapy regimens." - Anonymous Online Contributor
What is the total sample size for this medical experiment?
"Affirmative. The information published on clinicaltrials.gov demonstrates that the trial, which was initially posted in October 16th 2020 is currently recruiting subjects. 30 individuals need to be enrolled at one medical facility." - Anonymous Online Contributor
To what extent does Venetoclax pose a risk to patients?
"The team at Power assigned Venetoclax a score of 1 due to its Phase 1 designation, indicating that there is limited evidence supporting the drug's safety and efficacy." - Anonymous Online Contributor
Are there any other trials that have utilized Venetoclax for therapeutic benefit?
"At present, there are 825 Venetoclax studies in progress with 170 of them reaching Phase 3. Toronto is the location for many of these trials while a total of 32578 sites provide access to clinical testing involving Venetoclax." - Anonymous Online Contributor